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Abstract
Background: Surveys and retrospective studies of patients with idiopathic pulmonary fibrosis (IPF) have shown a
significant diagnostic delay. However, the causes and risk factors for this delay are not known.
Methods: Dates at six time points before the IPF diagnosis (onset of symptoms, first contact to a general
practitioner, first hospital contact, referral to an interstitial lung disease (ILD) centre, first visit at an ILD centre, and
final diagnosis) were recorded in a multicentre cohort of 204 incident IPF patients. Based on these dates, the delay
was divided into specific patient-related and healthcare-related delays. Demographic and clinical data were used to
determine risk factors for a prolonged delay, using multivariate negative binomial regression analysis.
Results: The median diagnostic delay was 2.1 years (IQR: 0.9–5.0), mainly attributable to the patients, general
practitioners and community hospitals. Male sex was a risk factor for patient delay (IRR: 3.84, 95% CI: 1.17–11.36, p =
0.006) and old age was a risk factor for healthcare delay (IRR: 1.03, 95% CI: 1.01–1.06, p = 0.004). The total delay was
prolonged in previous users of inhalation therapy (IRR: 1.99, 95% CI: 1.40–2.88, p < 0.0001) but not in patients with
airway obstruction. Misdiagnosis of respiratory symptoms was reported by 41% of all patients.
Conclusion: Despite increased awareness of IPF, the diagnostic delay is still 2.1 years. Male sex, older age and
treatment attempts for alternative diagnoses are risk factors for a delayed diagnosis of IPF. Efforts to reduce the
diagnostic delay should focus on these risk factors.
Trial registration: This study was registered at http://clinicaltrials.gov (NCT02772549) on May 10, 2016.
Keywords: IPF, Diagnosis, Delay, Cohort, Observational
Background
Idiopathic Pulmonary Fibrosis (IPF) is a debilitating
chronic lung disease. Despite recent advances in antifi-
brotic therapy, the prognosis is poor with a median sur-
vival of 2–5 years [1, 2]. The diagnosis of IPF can be
challenging, and due to its rarity, few physicians gain
enough expertise to become familiar with the disease. In
addition, the diagnosis often requires a multidisciplinary
team, which is not available in all centres [3, 4]. Surveys
and retrospective studies have shown a significant diag-
nostic delay from the onset of symptoms until the final
diagnosis is made [5–8]. This results in a delayed start of
effective antifibrotic treatment and lung transplant
evaluation, and can affect the disease course and
prognosis [5]. Current medical treatment of IPF can slow
down the progression of the disease but does not seem
to reverse any fibrotic changes that already have oc-
curred [9–11]. Timely diagnosis is therefore important
in order to initiate early treatment, prevent lung tissue
from developing fibrosis, delay disease progression and
prolong survival [4, 8].
The cause of the diagnostic delay is not well known
but is probably multifactorial. Surveys suggest that mis-
interpretation of respiratory symptoms could be a con-
tributing factor [6, 12]. The first symptoms of IPF are
often cough and shortness of breath, which are often at-
tributed to old age, smoking or more common cardio-
vascular or respiratory diseases by either the patient or
healthcare professionals as it is the case in patients with
chronic obstructive pulmonary disease (COPD) [13].
The distribution of the diagnostic delay between
patient-related and healthcare-related causes is still
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largely unknown. Moreover, we are not aware of any
studies detailing the risk factors for a delayed diagnosis.
A thorough understanding of these risk factors is essen-
tial for any attempts to reduce the diagnostic delay.
To answer these questions, we used a well character-
ized multicentre cohort of incident IPF patients to inves-
tigate the diagnostic delay and determine specific risk
factors for a delayed diagnosis.
Materials and methods
Patient cohort
The Pulmonary Fibrosis Biomarker (PFBIO) cohort pro-
spectively recruits incident patients with IPF from two
large interstitial lung disease (ILD) centres in Denmark
serving a population of 4.2 million. The main purpose of
the cohort is to follow a broad population of patients
with IPF and create a biorepository for biomarker re-
search. Antifibrotic therapy is centralized in Denmark
and referral to one of the three specialized ILD centres
is necessary for patients to be eligible for treatment. Re-
cruitment for the PFBIO cohort started in 2016 and is
still ongoing at one of the participating centres (Gentofte
Hospital) for future studies. At the time of analysis, the
cohort had included 204 patients. All participants had
received a diagnosis of IPF according to the 2011 ATS/
ERS/JRS/ALAT guidelines at an ILD centre, based on a
multidisciplinary team approach [3, 14]. Patients were
recruited on the same day as they received the diagnosis
or up to a maximum of two months later but prior to
initiating antifibrotic treatment. All patients with IPF
were eligible for participation unless they were unable to
provide written informed consent. A flowchart of the re-
cruitment process is presented in the Additional files 1.
Data collection
Patients completed a detailed survey at the time of diag-
nosis which was followed up by an interview if needed for
clarification (see Additional file 1). The survey included
questions about the onset of symptoms, initial healthcare
contact, smoking history, alternative diagnoses for respira-
tory symptoms, and previous therapies. The patients’
quality of life was assessed by the St. George’s Respiratory
Questionnaire (SGRQ) with higher scores indicating
worse quality of life [15]. Several measures of disease
severity were collected from the patients’ electronic re-
cords: comprehensive pulmonary function tests with spir-
ometry and diffusing capacity for carbon monoxide
(DLCO), six-minute walk test (6MWT) and high reso-
lution computed tomography (HRCT) scan.
The diagnostic delay was calculated based on six
pre-defined time points on the patients’ path towards an
IPF diagnosis (Fig. 1). The first two time points (dates of
symptom onset and first contact with a general practi-
tioner) were part of the survey which was completed by
each patient shortly after their diagnosis. All remaining
time points were collected from the patients’ electronic re-
cords. The specific delays were calculated from these time
points and are illustrated in Fig. 1. If a time point was not
relevant in a patient’s path towards an IPF diagnosis (i.e. if
the first contact with a physician was at a community hos-
pital or if a patient was referred directly to an ILD centre
by the general practitioner), the jumped delay was ex-
cluded for that patient in the statistical analysis.
Statistical analysis
Descriptive data are presented as frequency tables, mean
(SD) or median (interquartile range, IQR) as appropriate
for the data. Univariate analyses of baseline characteris-
tics were performed with a t-test or chi-squared test as
appropriate for the data.
None of the specific delays were normally distributed
and are presented as medians with IQR. We used multi-
variate negative binomial regression models to deter-
mine specific risk factors for patient delay, healthcare
delay and total delay respectively, as the delays were
counts of days and did not fit a Poisson distribution.
Covariates were tested for normality before inclusion
into any statistical analysis. Missing data were handled by
listwise deletion using complete cases without any imput-
ation of data.
Ethics, consent and permissions
All participants were included after written informed con-
sent, and none had chosen to withdraw from the study at
the time of analysis. The study has been approved by the
Capital Region regional ethics committee (H-16001790)
and the Danish Data Protection Agency (HGH-2016-017).
The study was also registered at http://clinicaltrials.gov
Fig. 1 Diagnostic delay from patients’ awareness of symptoms until an IPF diagnosis is made. The total delay is divided into patient delay and
healthcare delay (GP delay, hospital delay, waiting delay and specialized delay combined)
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(NCT02772549). We conducted the study according to
the principles of the Declaration of Helsinki and adhered
to the STROBE guidelines.
Results
The baseline characteristics of the 204 participants in the
PFBIO cohort are listed in Table 1. Patients were stratified
according to length of total diagnostic delay above or below
2 years. Demographic data such as age and sex were similar
in both groups, but there was a trend towards more
never-smokers among patients with a long total delay
(Table 1). Patients with a total delay of more than two years
were more frequently treated with inhalation therapy prior
to their diagnosis but without a marked increase in airway
obstruction, defined by a FEV1/FVC ratio below 0.7 (Table
1). Patients with a long delay also tended to have a higher
SGRQ total score and more frequently had a UIP pattern
on the diagnostic HRCT, which however did not reach stat-
istical significance (Table 2). Although rarely performed,
transbronchial cryobiopsies were more common in patients
with a short delay (Table 2). We were unable to calculate
total delay for 14 patients, due to imprecise data about their
onset of symptoms. Baseline data for this group is pre-
sented in the Additional file 1.
Referral pattern
Forty (20%) patients reported three or more visits to
their general practitioner before being referred further to
a secondary care hospital. When referred to the ILD
centres, the majority of patients had been investigated at
other community hospitals (n = 169, 83%), and only
rarely were referred directly from a private respiratory
physician (n = 6, 3%) or a general practitioner (n = 29,
14%). The IPF diagnosis was already suggested at the
Table 1 Baseline characteristics of participants with a delay above or below 2 years
All patients (n = 204) Total delay > 2 years (n = 98) Total delay < 2 years (n = 92) P-value
Age (years), mean (SD) 73.7 (7.8) 73.2 (8.0) 73.5 (7.6) 0.79
Sex 0.79
Male, n (%) 158 (77.5%) 74 (75.5%) 71 (77.2%)
Female, n (%) 46 (22.5%) 24 (24.5%) 21 (22.8%)
Smoking status 0.28
Never, n (%) 52 (25.6%) 31 (31.6%) 20 (21.7%)
Active, n (%) 14 (6.9%) 6 (6.1%) 8 (8.7%)
Former, n (%) 137 (67.5%) 61 (62.2%) 64 (69.6%)
Pack-years, median (IQR) 25.0 (11.8–40.0) 26.5 (10.9–40.0) 20.0 (10.8–41.7) 0.68
BMI (kg/m2), mean (SD) 27.4 (4.6) 28.0 (4.4) 26.8 (4.9) 0.08
Education 0.67
No higher education, n (%) 101 (54.9%) 52 (56.5%) 47 (53.4%)
Higher education, n (%) 83 (45.1%) 40 (43.5%) 41 (46.6%)
Previous use of inhalation therapy < 0.01
No, n (%) 143 (70.1%) 59 (60.2%) 76 (82.6%)
Yes, n (%) 61 (29.9%) 39 (39.8%) 16 (17.4%)
Airway obstruction at baseline 0.75
No, n (%) 179 (88.2%) 87 (88.8%) 83 (90.2%)
Yes, n (%) 24 (11.8%) 11 (11.2%) 9 (9.8%)
FVC (l), mean (SD) 3.0 (0.8) 3.0 (0.8) 3.1 (0.9) 0.60
FVC (% pred.), mean (SD) 88.9 (19.0) 87.9 (16.8) 91.1 (21.6) 0.25
DLCO (% pred.), mean (SD) 52.6 (13.6) 52.6 (13.6) 53.0 (13.5) 0.84
6MWT-distance (m), mean (SD) 441.7 (106.5) 444.8 (108.1) 448.3 (93.2) 0.82
SaO2 at rest (%), mean (SD) 96.2 (1.9) 96.3 (1.8) 96.2 (1.9) 0.82
SaO2 after 6MWT (%), mean (SD) 88.2 (7.7) 88.2 (7.0) 88.3 (8.2) 0.92
SGRQ total score, mean (SD) 39.1 (19.6) 41.4 (17.8) 37.2 (21.4) 0.20
SD standard deviation, IQR interquartile range, FVC forced vital capacity, DLCO diffusion capacity for carbon monoxide, 6MWT six-minute walk test, SGRQ St.
George’s Respiratory Questionnaire
Total delay could not be calculated for 14 patients due to the lack of data about onset of symptoms (baseline data of these patients are listed in the Additional
file). Airway obstruction was defined as FEV1/FVC < 0.7
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referring community hospital in 18 (9%) patients before
referral.
Most patients from community hospitals were referred
from a department of respiratory medicine (n = 133,
65%). Fewer patients were referred from departments of
internal medicine (n = 17, 8%), cardiology (n = 5, 2%),
emergency departments (n = 3, 1%) or other departments
(n = 10, 5%).
We were able to calculate a total incidence of 2.9 IPF
patients per 100,000 persons per year for the eastern
part of the country (served by one of the participating
ILD centres) where complete data were available. Data
on incident IPF patients who were not included in the
cohort were not available from other centres and these
could thus not be used in estimating the incidence (see
Additional file 1 for details).
Diagnostic delay
The median total diagnostic delay was 2.1 years (IQR:
0.9–5.0) and was stable during the study period (see
Additional file 1). The delay was mainly attributable to:
1) The patients (onset of symptoms until the first
healthcare contact) with a median delay of 0.1 years
(IQR: 0–0.9) (Fig. 2).
2) The general practitioners (first contact with a
general practitioner until referral to secondary
healthcare) with a median delay of 0.4 years
(IQR: 0.2–1.2) (Fig. 2).
3) The community hospitals (first visit due to the
current respiratory symptoms until referral to an
ILD centre) with a median delay of 0.4 years
(IQR: 0.1–1.9) (Fig. 2).
The delay due to waiting time (referral to an ILD centre
until the first patient visit at this hospital) was 0.2 years
(IQR: 0.1–0.3) and the specialized diagnostic workup (first
visit at the ILD centre until the final diagnosis) was 0.1
years (IQR: 0–0.3) (Fig. 2). As the diagnostic HRCT scan
typically was performed during the waiting time, the me-
dian time from the HRCT scan until the final diagnosis
was 0.3 years (IQR: 0.1–0.4). Due to highly skewed data of
all specific delays, the median total delay was longer than
the sum of all specific median delays (Fig. 2).
Risk factors for diagnostic delay
In multivariate negative binomial regression analysis, pa-
tient delays were prolonged in males and previous inhal-
ation therapy users. Healthcare delays were prolonged in
older patients and previous inhalation therapy users.
The combined total delay was prolonged in previous in-
halation therapy users but not influenced by sex, age or
proven obstructive lung disease (Table 3, Fig. 3).
Clinical findings at the time of diagnosis were also as-
sociated with the diagnostic delay (Table 3). Longer pa-
tient delays and healthcare delays were associated with
preserved DLCO and high SGRQ total score at the time
of diagnosis. Consequently, longer total delays were also
associated with preserved DLCO, high SGRQ total score
Table 2 Diagnostic procedures performed for the IPF diagnosis
All patients (n = 204) Total delay > 2 years (n = 98) Total delay < 2 years (n = 92) P-value
HRCT pattern 0.27
UIP, n (%) 142 (73.2%) 75 (78.1%) 59 (67.8%)
Possible UIP, n (%) 39 (20.1%) 16 (16.7%) 20 (23.0%)
Not UIP, n (%) 13 (6.7%) 5 (5.2%) 8 (9.2%)
BAL performed
No, n (%) 120 (58.8%) 60 (61.2%) 49 (53.3%) 0.27
Yes, n (%) 84 (41.2%) 38 (38.8%) 43 (46.7%)
Surgical lung biopsy performed 0.25
No, n (%) 180 (88.2%) 83 (84.7%) 83 (90.2%)
Yes, n (%) 24 (11.8%) 15 (15.3%) 9 (9.8%)
Cryobiopsy performed 0.02
No, n (%) 188 (92.2%) 95 (96.9%) 81 (88.0%)
Yes, n (%) 16 (7.8%) 3 (3.1%) 11 (12.0%)
Velcro crackles on lung auscultation 0.32
No, n (%) 26 (13.6%) 13 (14.1%) 8 (9.3%)
Yes, n (%) 165 (86.4%) 79 (85.9%) 78 (90.7%)
HRCT high resolution computed tomography, UIP usual interstitial pneumonia, BAL Bronchoalveolar lavage
The HRCT pattern is classified according to 2011 ATS/ERS/JRS/ALAT guidelines [12]
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but also a usual interstitial pneumonia (UIP) pattern on
HRCT at the time of diagnosis (Table 3).
Alternative diagnoses and treatments
Misdiagnosis was common with respiratory symp-
toms being attributed to at least one alternative
diagnosis in 82 (41%) participants before an IPF
diagnosis was established (Table 4). Of these, 62 had
received treatment for the alternative diagnosis for a
median duration of 7.0 months. Heart disease was
the most common misdiagnosis (n = 25, 12%)
followed by obstructive lung disease (Table 4). How-
ever, of the 61 participants with a history of inhal-
ation therapy use, only 20 (33%) fulfilled the
diagnostic criteria for either asthma or COPD. Treat-
ment with inhalation therapy increased the total
diagnostic delay in patients with and without proven
obstructive lung disease (Fig. 3).
Table 3 Incidence rate ratio (IRR) of several risk factors for patient delay, healthcare delay and total delay, assessed by multivariate
negative binomial regression
Patient delay Healthcare delay Total delay
IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value
Patient characteristics
Age 0.97 0.92–1.02 0.24 1.03 1.01–1.06 0.004* 1.01 0.98–1.03 0.59
Male sex 3.84 1.17–11.36 0.006* 1.01 0.68–1.49 0.95 0.99 0.66–1.48 0.97
Ever smokers 1.34 0.48–3.35 0.51 0.78 0.54–1.11 0.18 0.79 0.54–1.14 0.19
Higher education 2.16 0.91–5.18 0.06 1.28 0.91–1.81 0.14 1.15 0.83–1.60 0.39
Previous use of inhalation therapy 4.68 1.77–13.37 0.0004* 1.98 1.38–2.90 < 0.0001* 1.99 1.40–2.88 < 0.0001*
Clinical findings at diagnosis
DLCO (%) 1.05 1.02–1.08 0.005* 1.02 1.01–1.03 0.006* 1.02 1.00–1.03 0.02*
FVC (%) 1.02 0.99–1.05 0.06 1.00 0.99–1.01 0.96 1.00 0.99–1.01 0.67
Airway obstruction 1.10 0.23–3.86 0.89 1.57 0.86–2.66 0.11 1.61 0.94–2.61 0.07
SGRQ total score 1.03 1.01–1.07 0.004* 1.01 1.00–1.03 0.003* 1.02 1.01–1.03 0.001*
UIP pattern on HRCT 0.84 0.30–2.11 0.71 1.32 0.89–1.95 0.16 1.47 1.01–2.11 0.04*
CI confidence interval, DLCO diffusion capacity for carbon monoxide, 6MWT six-minute walk test, SGRQ St. George’s Respiratory Questionnaire, HRCT high
resolution computed tomography, UIP usual interstitial pneumonia *p-value < 0.05
Values of DLCO, FVC and SGRQ-score are obtained at the time of diagnosis. Airway obstruction is defined as FEV1/FVC < 0.7
Fig. 2 Duration (median, IQR) of total and specific delays due to patient, general practitioner, community hospitals, waiting time and ILD centres.
Time periods of the specialized delays are truncated at 5 years to increase legibility. Note different time scales
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A total of 51% of patients reported at least one occur-
rence of pneumonia during the two years before their
IPF diagnosis, while 49% received treatment for at least
one instance of pneumonia (Table 4).
Thirty-five (18%) of all participants had received at least
one prescription of prednisolone or other immunosuppres-
sive treatment before referral. A large proportion of patients
(42%) had received a prescription of proton pump inhibitor
(PPI) and 32% also reported taking over-the-counter ant-
acid therapy (Table 4). None of the patients were treated
with specific antifibrotic treatment until they received their
diagnosis of IPF at the ILD centres.
Discussion
We studied the referral pattern and diagnostic delay in a
cohort of IPF patients and found that it was mainly at-
tributable to patients, general practitioners and commu-
nity hospitals. Previous inhalation therapy use was a
major risk factor for a delayed diagnosis. Male sex was
associated with a prolonged patient delay and older age
was associated with a prolonged healthcare delay. Pa-
tients were often misdiagnosed and treated before a final
diagnosis of IPF was made.
We present for the first time a detailed description of
IPF patients’ path towards the IPF diagnosis and the dif-
ferent components of the diagnostic delay in incident
patients and thus with limited recall bias. We highlight
the three main sources of delay: patients themselves,
general practitioners and community hospitals (most
commonly departments of respiratory medicine). Future
efforts to reduce the diagnostic delay should be directed
at these three sources which could be achieved by fur-
ther increasing awareness of IPF among patients, general
practitioners and hospital physicians (both pulmonolo-
gists and other specialists). However, while the delay at
ILD centres often was shorter, it still contributed to the
total delay in many patients and the median time from
the diagnostic HRCT until the final diagnosis was still
0.3 years. Therefore, there is a potential for interventions
to shorten the delay at all steps towards the IPF diagno-
sis, which should be further explored. A delay, however,
is not always the result of a mistake or missed diagnosis.
It is possible that some patients were delayed because
they did not fulfil diagnostic criteria for IPF during the
early stages of their disease, which is a recognized limita-
tion of the 2011 ATS/ERS/JRS/ALAT guidelines [16].
We expected a shortened diagnostic delay due to an
increased awareness of IPF during recent years which
unfortunately could not be confirmed. The availability of
pharmacological treatments during the past few years re-
sulted in an increase in the number of patients referred
to ILD centres, but this increase has so far failed to im-
pact the diagnostic delay in IPF [7]. We found a median
total diagnostic delay of 2.1 years, which is similar to
previous reports of IPF patients and general ILD popula-
tions, despite new treatment options, new diagnostic
guidelines and increased awareness of IPF [4–8, 17–20].
In addition to the median length of the diagnostic
delay of 2.1 years, we found a high spread of the specific
and total delays with 25% of patients having a delay of
more than 5 years. This finding contributes to the evolv-
ing understanding that some patients with IPF can have
a slowly progressive phenotype [1]. However, some pa-
tients reported very long delays of up to 20 years, which
are unlikely to be due to symptoms caused by IPF. Ra-
ther, the patient-reported symptoms could be caused by
an alternative disease, such as cardiovascular disease or
COPD, which are common comorbidities in patients
with IPF [21]. In addition, recall bias can affect the pa-
tients’ ability to remember important information about
the onset of their symptoms. However, the specific
healthcare delays are defined by objective data from
Fig. 3 Length of total delay in participants stratified according to obstructive lung disease (asthma or COPD) and previous use of
inhalation therapy
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electronic records and support the hypothesis of a
phenotype with slowly progressive IPF. The possible
identification of interstitial lung abnormalities on lung
CT many years prior to the development of clinical
interstitial lung disease further contributes to this obser-
vation [22–24].
A first step to reduce the diagnostic delay is to identify
risk factors for a delay and recognize target groups for
interventions. We are unaware of previous studies pro-
viding estimates of risk factors for a delayed diagnosis of
IPF. Interestingly, the risk factors for patient delay differ
from those for healthcare delay. The previous use of in-
halation therapy and male sex were risk factors for a
prolonged patient delay. The increased delay in previous
inhalation therapy users could be attributable to
treatment attempts with inhalation therapy for unex-
plained respiratory symptoms in the primary care sector,
which has been suggested previously [12, 18]. Airway
obstruction was not a risk factor for a diagnostic delay,
which indicates frequent futile treatment attempts with
inhalation therapy in patients without obstructive lung
disease. However, it is possible that an obstructive lung
disease was masked by a concomitant reduction in FVC
in some patients. While treatment attempts with inhal-
ation therapy can be warranted in patients with unex-
plained respiratory symptoms, these patients should be
closely monitored and referred for further workup when
symptoms do not improve. In addition, a correctly per-
formed and interpreted spirometry could help to quickly
rule out airway obstruction as a cause of breathlessness
in these patients. Improved diagnostic tools, including
screening or effective diagnostic biomarkers, would
make the diagnosis more accessible, also for non-ILD
specialists, and are desperately needed.
Patients with a prolonged delay had relatively pre-
served DLCO at the time of diagnosis, suggesting that
patients with more severe IPF were quickly diagnosed.
On the other hand, patients with a prolonged delay re-
ported a high symptom burden as indicated by a higher
SGRQ total score. This apparent discrepancy could be
explained by the complexity of quality of life data, which
can be impacted by many factors, including a prolonged
diagnostic delay but also by comorbidities, misdiagnosis,
treatment and multiple healthcare contacts. Besides, the
SGRQ total score has limitations in quantifying disease
severity in IPF patients [25].
Patients reported frequent misdiagnosis prior to their
final IPF diagnosis, which is in line with the presented
risk factors for a diagnostic delay, and with previous pa-
tient surveys [12, 17, 20]. The frequent treatment with
inhalation therapy for obstructive lung disease, despite
the lack of airway obstruction, confirms this problem. In
addition, the previous treatments were often given for
long periods (median duration of treatment was 7.0
months) and included potentially harmful treatments
such as prednisolone and other immunosuppressive
drugs, which are often prescribed for other fibrotic lung
disease such as chronic hypersensitivity pneumonitis, a
common differential diagnosis to IPF. The frequent oc-
currences of pneumonia in the two years prior to the
IPF diagnosis could either be due to an increased risk of
infection in patients or misinterpretation of crackles on
auscultation. Screening for finger clubbing and velcro
crackles on auscultation, particularly if they do not re-
solve after treatment of suspected pneumonia, should
prompt further diagnostic evaluation [26]. A treatment
attempt for any suspected disease prolongs the diagnos-
tic delay, and most importantly delays the initiation of
effective antifibrotic treatment. Early referral of patients
Table 4 Previous diagnosis and treatment before an IPF
diagnosis was made
All patients (n = 204)
Alternative diagnoses for respiratory symptoms
Heart disease 25 (12.3%)
Asthma 17 (8.3%)
Chronic bronchitis 11 (5.4%)
COPD 10 (4.9%)
Emphysema 3 (1.5%)
Other 18 (8.8%)
Reports of pneumonia during the previous 2 years before IPF diagnosis
0 88 (49.2%)
1 32 (17.9%)
2 28 (15.6%)
3 or more 31 (18.0%)
Antibiotic courses for pneumonia during the previous 2 years before IPF
diagnosis
0 91 (50.6%)
1 35 (19.4%)
2 31 (17.2%)
3 or more 23 (11.3%)
Previous medical treatments
Inhalation therapy
SABA 39 (19.1%)
LABA 29 (14.2%)
LAMA 21 (10.3%)
ICS 26 (12.7%)
Prednisolone 34 (16.7%)
Other immunosuppressive treatmenta 5 (2.5%)
Proton pump inhibitor or H2-receptor antagonist 85 (41.7%)
Antacids 57 (31.7%)
SABA short acting beta agonist, LABA long acting beta agonist, LAMA long
acting muscarinic antagonist, ICS inhaled corticosteroid. aAzathioprine (n = 2),
mycophenolate mofetil, oral budesonide and cyclophosphamide (each n = 1)
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with an uncertain diagnosis to a centre with expertise in
ILD is essential and could contribute to shortening the
diagnostic delay.
Based on data from one participating centre, we could
estimate an annual incidence of 2.9 IPF patients per
100,000 inhabitants per year. However, it might be sus-
pected that some older and frail patients, or patients
with severe comorbidities, were not referred for a diag-
nostic workup at an ILD centre. Our calculated inci-
dence is in the lower end of the range of other estimates
(0.6–17.4 cases of IPF per 100,000 inhabitants per year)
which suggests a continuing underdiagnosis of IPF [27].
Previous reports have often been performed retrospect-
ively or are based on registries and insurance claims
(which can overestimate incidence due to miscoding)
and many estimates predate the current diagnostic
guidelines [27–29]. In contrast to several previous stud-
ies, all patients included in our cohort had a confident
IPF diagnosis confirmed at a specialised ILD centre. A
Danish study estimated the IPF incidence in 2003–2009
to be 1.3 patients per 100,000 inhabitants per year [7].
Thus, despite the apparent underdiagnosis, we can con-
firm a general increase in the incidence of IPF diagnosis
in a comparable setting.
Our study has several strengths but also some limita-
tions. A major strength is the prospective inclusion of a
large part of all incident IPF patients in two ILD centres
in the region increasing the generalizability of the re-
sults. In addition, we included patients immediately after
their IPF diagnoses, thus reducing recall bias of import-
ant information, such as the date of symptom onset.
However, as most patients experienced a diagnostic
delay of several years, there remains a risk of recall bias
in our cohort. Wherever possible, time points were ex-
tracted from electronic medical records, resulting in
more reliable data compared with surveys with patient
reported data. However, some data were still patient re-
ported, and thus not entirely objective. This includes the
date of symptom onset and the first healthcare contact.
These data are inherently subjective and could not have
been collected in a different manner. The definition of
symptom onset can also be debated. Many patients with
IPF have comorbidities which could give respiratory
symptoms (i.e., cardiovascular disease or COPD) making
it difficult to define the onset of symptoms caused by
IPF. However, proven obstructive pulmonary disease was
not a risk factor for a prolonged delay.
Our study was performed in one single country and
findings cannot simply be generalized to other countries
and healthcare systems. While treatment of IPF in
Denmark is centralised to a few ILD centres, it may not
be in other countries, potentially leading to more missed
or delayed diagnoses. Also, the organization and respon-
sibilities of primary, secondary and tertiary care differ
between countries. Due to these differences, we consid-
ered the combined healthcare delay in the statistical ana-
lyses, rather than the specific delays (general
practitioner, community hospital or ILD centre). Never-
theless, we believe that patients with IPF in other health
systems will meet the same obstacles on their path to-
wards a diagnosis of IPF, due to the rarity of the condi-
tion and the difficulty in establishing a confident
diagnosis.
Conclusion
In conclusion, this study has shown that diagnostic delay
in IPF is mainly attributable to patients, general practi-
tioners and community hospitals. Patients were often
misdiagnosed and treated before a final diagnosis of IPF
was made. Previous inhalation therapy use was a major
risk factor for a delayed diagnosis, and male sex and
older age were risk factors for patient delay and health-
care delay respectively. Efforts to reduce the diagnostic
delay should focus on these risk factors.
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